BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1353 related articles for article (PubMed ID: 26341193)

  • 1. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
    Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
    Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor acidity, chemoresistance and proton pump inhibitors.
    De Milito A; Fais S
    Future Oncol; 2005 Dec; 1(6):779-86. PubMed ID: 16556057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug repurposing for anticancer therapies. A lesson from proton pump inhibitors.
    Spugnini EP; Fais S
    Expert Opin Ther Pat; 2020 Jan; 30(1):15-25. PubMed ID: 31847622
    [No Abstract]   [Full Text] [Related]  

  • 6. Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism.
    Fais S
    J Intern Med; 2010 May; 267(5):515-25. PubMed ID: 20433578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of extracellular acidity on resistance to chemotherapy treatment: a systematic review.
    da Silva VP; Mesquita CB; Nunes JS; de Bem Prunes B; Rados PV; Visioli F
    Med Oncol; 2018 Oct; 35(12):161. PubMed ID: 30377828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The multi-factorial nature of clinical multidrug resistance in cancer.
    Assaraf YG; Brozovic A; Gonçalves AC; Jurkovicova D; Linē A; Machuqueiro M; Saponara S; Sarmento-Ribeiro AB; Xavier CPR; Vasconcelos MH
    Drug Resist Updat; 2019 Sep; 46():100645. PubMed ID: 31585396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparanase: From basic research to therapeutic applications in cancer and inflammation.
    Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N
    Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
    Rohwer N; Cramer T
    Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repositioning of proton pump inhibitors in cancer therapy.
    Lu ZN; Tian B; Guo XL
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):925-937. PubMed ID: 28861639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LASS2 enhances chemosensitivity of breast cancer by counteracting acidic tumor microenvironment through inhibiting activity of V-ATPase proton pump.
    Fan S; Niu Y; Tan N; Wu Z; Wang Y; You H; Ke R; Song J; Shen Q; Wang W; Yao G; Shu H; Lin H; Yao M; Zhang Z; Gu J; Qin W
    Oncogene; 2013 Mar; 32(13):1682-90. PubMed ID: 22580606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surmounting cancer drug resistance: New insights from the perspective of N
    Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
    Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton channels and exchangers in cancer.
    Spugnini EP; Sonveaux P; Stock C; Perez-Sayans M; De Milito A; Avnet S; Garcìa AG; Harguindey S; Fais S
    Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2715-26. PubMed ID: 25449995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics.
    Wijdeven RH; Pang B; Assaraf YG; Neefjes J
    Drug Resist Updat; 2016 Sep; 28():65-81. PubMed ID: 27620955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondria and cancer chemoresistance.
    Guerra F; Arbini AA; Moro L
    Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):686-699. PubMed ID: 28161329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton pump inhibitors enhance chemosensitivity, promote apoptosis, and suppress migration of breast cancer cells.
    Ihraiz WG; Ahram M; Bardaweel SK
    Acta Pharm; 2020 Jun; 70(2):179-190. PubMed ID: 31955147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity.
    Sharma A
    Nanomedicine (Lond); 2017 Sep; 12(17):2137-2148. PubMed ID: 28805111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
    Wilting RH; Dannenberg JH
    Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton pump inhibitors for the treatment of cancer in companion animals.
    Walsh M; Fais S; Spugnini EP; Harguindey S; Abu Izneid T; Scacco L; Williams P; Allegrucci C; Rauch C; Omran Z
    J Exp Clin Cancer Res; 2015 Sep; 34(1):93. PubMed ID: 26337905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.